GeneTex
  • Country / Location Selection

United States (US)

PD-L1 antibody [ZR3]

Cat No. GTX01796

Host

Rabbit

Clonality

Monoclonal

Clone Name

ZR3

Isotype

IgG

Application

IHC-P

Reactivity

Human
Package
500 μl ($519)

APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.
Application Dilution
IHC-P 1:100-1:200

Note :

IHC-P
Pretreatment of deparaffinized tissue with heat-induced epitope retrieval or enzymatic retrieval is recommended.

Not tested in other applications.

Calculated MW

33 kDa. ( Note )

Positive Control

Placenta or lung adenocarcinoma

PROPERTIES

Form

Liquid

Buffer

Tris-HCl buffer, 0.2% BSA, < 0.1% sodium azide

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC.

Concentration

Batch dependent (Please refer to the vial label for the specific concentration.)

Antigen Species

Human

Immunogen

KLH-conjugated linear peptide corresponding to human PD-L1

Purification

Purified IgG

Conjugation

Unconjugated

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

TARGET

Synonyms

CD274 molecule , B7-H , B7H1 , PD-L1 , PDCD1L1 , PDCD1LG1 , PDL1

Cellular Localization

Cell membrane

Background

This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]

Database

Research Area

REFERENCE

There are currently no references for PD-L1 antibody [ZR3] (GTX01796). Be the first to share your publications with this product.

REVIEW

There are currently no reviews for PD-L1 antibody [ZR3] (GTX01796). Be the first to share your experience with this product.